MIS416 vaccine increased the proportion of splenic DCs at day 59 after tumor challenge, but did not significantly affect the proportion of macrophages or dual expressing F4/80+CD11c+ cells (Supplemental Figure 3a). The gene discussed is ITGAX; the disease is neoplasm.